Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.

Makis, William; McCann, Karey; Riauka, Terence A; McEwan, Alexander J B

Makis, William; McCann, Karey; Riauka, Terence A; McEwan, Alexander J B.

Affiliation

Makis W; From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.

Clin Nucl Med ; 40(11): 880-4, 2015 Nov.

Article in En | MEDLINE | ID: mdl-26359564

Subject(s)

Hyperaldosteronism/radiotherapy; Hypokalemia/radiotherapy; Liver Neoplasms/pathology; Neuroendocrine Tumors/radiotherapy; Octreotide/analogs & derivatives; Organometallic Compounds/therapeutic use; Pancreatic Neoplasms/radiotherapy; Radiopharmaceuticals/therapeutic use; Female; Humans; Liver Neoplasms/diagnostic imaging; Middle Aged; Neuroendocrine Tumors/diagnostic imaging; Neuroendocrine Tumors/secondary; Octreotide/therapeutic use; Pancreatic Neoplasms/diagnostic imaging; Pancreatic Neoplasms/secondary; Radionuclide Imaging

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Pancreatic Neoplasms / Octreotide / Neuroendocrine Tumors / Radiopharmaceuticals / Hyperaldosteronism / Hypokalemia / Liver Neoplasms Type of study: Prognostic_studies Limits: Female / Humans / Middle aged Language: En Journal: Clin Nucl Med Year: 2015 Document type: Article Affiliation country: Canada Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google